CTOs on the Move

Maze Therapeutics

www.mazetx.com

 
Maze Therapeutics is translating novel genetic insights into lifesaving medicines, through an approach that integrates human genetics and functional genomics.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.mazetx.com
  • 131 Oyster Point Blvd Suite 200
    South San Francisco, CA USA 94080
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Maze Therapeutics raised $191M on 02/28/2019
Maze Therapeutics raised $190M on 01/10/2022

Similar Companies

Quentis Therapeutics

Quentis is at the forefront of the next generation of immuno-oncology companies that are translating novel biology into new therapeutic approaches to help more patients benefit from immunotherapy.

ITOCHU Chemicals America

ITOCHU Chemicals America is a White Plains, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Caladrius

Caladrius is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of cell therapies designed to reverse disease and/or promote the regeneration of damaged tissue. The Company is developing first-in-class therapeutics based on the characteristics of naturally occurring CD34+ cells and their ability to stimulate the growth of new microvasculature. The Company`s platform technology leverages these cells to enable the body`s natural repair mechanisms using formulations unique to each medical indication.

ChemDiv

ChemDiv is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Vedanta Biosciences

The trillions of microbes that call us home – the human microbiome – perform critical functions that preserve our health including helping develop our immune system, manufacturing nutrients such as vitamins, and harvesting energy from the diet. Alterations of the human microbiome are increasingly recognized as a key factor in autoimmune, metabolic, infectious and many other diseases. For millions of years, humans have co-evolved with this community of microbes, communicating in an ancient language that holds critical clues about how autoimmune and infectious diseases develop. This language is based on a system of signals that our resident microbes use to successfully colonize us, such as byproducts of bacterial metabolism and factors that bacteria use to adapt to human niches. Recent discoveries have shown that most of these signals do not lead to disease, rather, they promote our long-term survival. Vedanta Biosciences is developing an innovative class of therapies that modulate pathways of interaction between the human microbiome and the host immune system. Vedanta Biosciences was co-founded by PureTech and a group of world renowned experts in immunology and microbiology.